A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Trial Profile

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Mirvetuximab soravtansine (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoGen
  • Most Recent Events

    • 06 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2019.
    • 19 Dec 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
    • 19 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top